Tensions have risen between White House officials and HHS Secretary Alex Azar; a life-saving bladder cancer drug is in short supply; suicide rates for children and young adults have soared.
Tensions have widened the rift between White House officials and HHS Secretary Alex Azar, POLITICO reported, resulting in impeded projects, disputes over Medicaid and fetal tissue research, complicating drug pricing reform, and spurring personal attacks, according to current and former White House aides and HHS officials. The White House called the disagreements part of the deliberative policy process while HHS downplayed the disputes. Azar is believed not to be at risk of being fired despite the recent tensions.
While drug shortages are sometimes caused by production errors, quality problems, and natural disasters, the example of a low-cost, gold standard immunotherapy drug for bladder cancer illustrates another reason—some believe the price is set too low and discourage others from making the off-patent drug. Desperate patients are searching for a Merck drug, called BCG, a live, weakened bacteria that takes 3 months to make, The Washington Post reported.
A study in JAMA found that suicide rates for teens and young adults have reached the highest level since 2000, especially for young men, while the rate for females steadily increased. A total of 5016 males and 1225 females between 15 to 24 years old took their own lives in 2017. At ages 15 to 19 years, the rate of suicides was 11.8 per 100,000 (17.9 per 100,000 in males and 5.4 per 100,000 in females). In young adults aged 20 to 24 years, the suicide rate for males and females combined in 2017 was 17 per 100,000; in males, 27.1 per 100,000; and in females, 6.2 per 100,000.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen